al • da • tu [ɒl - də - tu]: to become something different

Aldatu Biosciences Navigation
  • PRODUCTS
    • HIV Drug Resistance
    • Pandemic Preparedness – VHFs
    • • Lassa fever
    • • Crimean-Congo hemorrhagic fever
    • • Ebola and Marburg
    • • Yellow fever virus
    • Pandemic Preparedness – SARS-CoV-2
    • • SARS-CoV-2 [Detection]
    • • SARS-CoV-2 [Variant Genotyping]
    • Enzymes
      • Hot Start RT
  • ABOUT
    • Technology
    • Our Story
    • Quality
    • Careers
    • News
    • Contact
  • PRODUCT PIPELINE
  • MY ACCOUNT
    • Dashboard
    • Orders
    • Account details
  • 🛒 0
  • Search
  • PRODUCTS
    • HIV Drug Resistance
    • Pandemic Preparedness – VHFs
    • • Lassa fever
    • • Crimean-Congo hemorrhagic fever
    • • Ebola and Marburg
    • • Yellow fever virus
    • Pandemic Preparedness – SARS-CoV-2
    • • SARS-CoV-2 [Detection]
    • • SARS-CoV-2 [Variant Genotyping]
    • Enzymes
      • Hot Start RT
  • ABOUT
    • Technology
    • Our Story
    • Quality
    • Careers
    • News
    • Contact
  • PRODUCT PIPELINE
  • MY ACCOUNT
    • Dashboard
    • Orders
    • Account details
  • 🛒 0
  • Search

Post Archive by Month

Below you'll find a list of all posts from March, 2015

Aldatu Biosciences Receives $1.5 Million Direct-to-Phase II SBIR Grant from the NIAID for HIV Drug Resistance Diagnostic Development

Cambridge, MA, 12th March 2015 (download press release .pdf) Aldatu Biosciences, a novel diagnostics platform company focused on improving HIV patient care globally, today announced it has been awarded a Direct-to-Phase …

Read More

ACCOUNT

  • Sign up
  • Login

OUR COMPANY

  • Products
  • Our Story
  • Technology

RESOURCES

  • News
  • Contact
  • Terms and Conditions
Facebook-f Twitter Linkedin-in

© 2023 ALDATU BIOSCIENCES 2023